JP2022523372A5 - - Google Patents
Info
- Publication number
- JP2022523372A5 JP2022523372A5 JP2021549416A JP2021549416A JP2022523372A5 JP 2022523372 A5 JP2022523372 A5 JP 2022523372A5 JP 2021549416 A JP2021549416 A JP 2021549416A JP 2021549416 A JP2021549416 A JP 2021549416A JP 2022523372 A5 JP2022523372 A5 JP 2022523372A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025034340A JP2025102775A (ja) | 2019-02-22 | 2025-03-05 | Ｃｄ３８に特異的に結合する抗体、レナリドミド、及びデキサメタゾンの組み合わせを用いて、新たに診断された多発性骨髄腫を治療する方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962809070P | 2019-02-22 | 2019-02-22 | |
| US62/809,070 | 2019-02-22 | ||
| US201962829814P | 2019-04-05 | 2019-04-05 | |
| US201962829791P | 2019-04-05 | 2019-04-05 | |
| US201962829804P | 2019-04-05 | 2019-04-05 | |
| US62/829,791 | 2019-04-05 | ||
| US62/829,804 | 2019-04-05 | ||
| US62/829,814 | 2019-04-05 | ||
| PCT/IB2020/051484 WO2020170211A1 (en) | 2019-02-22 | 2020-02-21 | Methods of treating newly diagnosed multiple myeloma with a combination of an antibody that specifically binds cd38, lenalidomide and dexamethasone |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025034340A Division JP2025102775A (ja) | 2019-02-22 | 2025-03-05 | Ｃｄ３８に特異的に結合する抗体、レナリドミド、及びデキサメタゾンの組み合わせを用いて、新たに診断された多発性骨髄腫を治療する方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022523372A JP2022523372A (ja) | 2022-04-22 |
| JPWO2020170211A5 JPWO2020170211A5 (https=) | 2023-06-27 |
| JP2022523372A5 true JP2022523372A5 (https=) | 2023-06-27 |
| JP7721445B2 JP7721445B2 (ja) | 2025-08-12 |
Family
ID=72141407
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021549416A Active JP7721445B2 (ja) | 2019-02-22 | 2020-02-21 | Ｃｄ３８に特異的に結合する抗体、レナリドミド、及びデキサメタゾンの組み合わせを用いて、新たに診断された多発性骨髄腫を治療する方法 |
| JP2025034340A Pending JP2025102775A (ja) | 2019-02-22 | 2025-03-05 | Ｃｄ３８に特異的に結合する抗体、レナリドミド、及びデキサメタゾンの組み合わせを用いて、新たに診断された多発性骨髄腫を治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025034340A Pending JP2025102775A (ja) | 2019-02-22 | 2025-03-05 | Ｃｄ３８に特異的に結合する抗体、レナリドミド、及びデキサメタゾンの組み合わせを用いて、新たに診断された多発性骨髄腫を治療する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20200268847A1 (https=) |
| EP (1) | EP3927376A4 (https=) |
| JP (2) | JP7721445B2 (https=) |
| CN (1) | CN113727729A (https=) |
| CA (1) | CA3131064A1 (https=) |
| WO (1) | WO2020170211A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| AU2015358615B2 (en) | 2014-12-04 | 2021-08-05 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute myeloid leukemia |
| MX389805B (es) | 2015-05-20 | 2025-03-11 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38. |
| DK3827845T3 (da) | 2015-11-03 | 2022-05-23 | Janssen Biotech Inc | Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf |
| JP2019527678A (ja) | 2016-06-28 | 2019-10-03 | ユーエムセー・ユトレヒト・ホールディング・ベー・フェー | ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療 |
| JP2021502961A (ja) | 2017-10-31 | 2021-02-04 | ヤンセン バイオテツク，インコーポレーテツド | 高リスク多発性骨髄腫の治療方法 |
| WO2023209555A1 (en) | 2022-04-26 | 2023-11-02 | Aragon Pharmaceuticals, Inc. | Approved drug products and methods for treating prostate cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9732154B2 (en) * | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| EP3834889A1 (en) * | 2014-06-16 | 2021-06-16 | Mayo Foundation for Medical Education and Research | Treating myelomas |
| US10617757B2 (en) * | 2014-08-08 | 2020-04-14 | The Regents Of The University Of California | Methods for treating multiple myeloma |
| US20170044265A1 (en) * | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
-
2020
- 2020-02-21 CN CN202080015963.2A patent/CN113727729A/zh active Pending
- 2020-02-21 WO PCT/IB2020/051484 patent/WO2020170211A1/en not_active Ceased
- 2020-02-21 JP JP2021549416A patent/JP7721445B2/ja active Active
- 2020-02-21 EP EP20759735.2A patent/EP3927376A4/en active Pending
- 2020-02-21 US US16/797,301 patent/US20200268847A1/en active Pending
- 2020-02-21 CA CA3131064A patent/CA3131064A1/en active Pending
-
2025
- 2025-03-05 JP JP2025034340A patent/JP2025102775A/ja active Pending